US Supreme Court Sides with Bayer, Limits Roundup Lawsuits

Key Facts

1The US Supreme Court ruled in favor of Bayer, limiting the scope of Roundup cancer lawsuits to help the company resolve thousands of claims.

2Bayer stock surged 20% following the Supreme Court ruling in its favor.

3The US Supreme Court scaled back Roundup cancer lawsuits against Bayer.

After years of legal uncertainty, the US Supreme Court delivered a decisive ruling in favor of Bayer, fundamentally altering the trajectory of Roundup cancer lawsuits. The court narrowed the scope of the claims, giving the company a clearer path to resolve thousands of pending cases. Bayer's stock surged 20% following the announcement, according to press reports.

These lawsuits have been a massive legal burden on Bayer since its acquisition of Monsanto in 2018. The ruling is expected to accelerate the settlement of remaining claims. At the close on June 24, Bayer (BAYRY) shares traded at $11.25, up from pre-ruling levels, with a high of $11.39 and a low of $11.17, per market data.

Investors are now watching Bayer's quarterly results due in July, which may reveal the ruling's impact on financial guidance. Markets are also monitoring potential appeals from plaintiffs that could return the case to lower courts. As of the June 24 close, the stock sits at $11.25, with resistance at $11.39 and support at $11.17.